ETF Managers Group’s Protalix BioTherapeutics PLX Stock Holding History

ETF Managers Group’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-101,768	Closed	-$397K	–	642
2020 Q3	$397K	Buy	101,768 +7,915	+8%	+$28.6K	0.01%	358
2020 Q2	$367K	Buy	+93,853	New	+$321K	0.01%	320
2018 Q4	–	Sell	-33,152	Closed	-$221K	–	589
2018 Q3	$221K	Buy	+33,152	New	+$166K	0.01%	242
2017 Q3	–	Sell	-8,981	Closed	-$73K	–	490
2017 Q2	$73K	Buy	+8,981	New	+$84.3K	0.01%	210

Other funds holding PLX

BCM

Burrage Capital Management Boston, Massachusetts $99.7M AUM 66.05% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

ETF Managers Group's PLX Position: Q4 2020 in Review

ETF Managers Group sold out of Protalix BioTherapeutics (PLX) in Q4 2020, closing a stake of 101,768 shares — an estimated $397K sold.

ETF Managers Group first reported a position in PLX in Q2 2017 and held it in 4 quarters. The position peaked at $397K in Q3 2020. 23 funds tracked by Wall St. Rank hold PLX as of Q4 2020.

ETF Managers Group reported no remaining Protalix BioTherapeutics position as of Q4 2020 after selling out during the quarter.
ETF Managers Group sold 101,768 Protalix BioTherapeutics shares in Q4 2020, an estimated $397K.
ETF Managers Group first reported a position in Protalix BioTherapeutics in Q2 2017 and held it in 4 quarters.
ETF Managers Group's Protalix BioTherapeutics position peaked at $397K in Q3 2020.
23 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2020.

Based on ETF Managers Group's 13F filing for Q4 2020, filed 16 Feb 2021.